Αρχική World News Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC... World News Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence Από Ogkologos - 21 Ιουλίου, 2026 217 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LITESPARK-022 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent... 24 Νοεμβρίου, 2025 Searching for novel connections in cancer metabolism 19 Ιουνίου, 2020 Man Gets His First Haircut In 15 Years To Join The... 21 Αυγούστου, 2019 When Caregiving Takes a Toll 28 Μαΐου, 2021 Φόρτωση περισσοτέρων HOT NEWS The Lung Immune Prognostic Index May Indicate Response to Immune Checkpoint... Study Improves the Quality of Biopsy Specimens for Cancer Research ASCO Annual Meeting 2023: Radiation Therapy May Not Be Needed After... Financial Navigation Can Reduce the Financial Toxicity of Cancer Care